"
Team:Arizona State/MHC
From 2013.igem.org
(Difference between revisions)
| Line 13: | Line 13: | ||
<body> | <body> | ||
| - | <h3>Recombinant expression of | + | <h3>Recombinant expression of FluM1 from Influenza & Melan-A from Melanoma provides protein epitope for antigen recognition</h3> |
| + | <p> | ||
| + | The BactoVax vaccine platform has been engineered to act as a general vaccine platform, suitable for vaccination against bacteria, viruses, and tumors. Our current system has been engineered to express both viral antigen FluM1 and cancer surface antigen Melan-A to illustrate the modular nature of the platform itself. Instead of having to engineer a separate vaccine for every single different strain of a particular disease or group of disease separately, BactoVax provides a chassis that can be easily modified simply by addition of the nucleotide sequence for antigen of interest to trigger a specialized immune response. | ||
| + | </p> | ||
<h3>MHC Pathway presentation Depends Upon Pathogenic characteristics</h3> | <h3>MHC Pathway presentation Depends Upon Pathogenic characteristics</h3> | ||
Revision as of 23:08, 27 September 2013
Recombinant expression of FluM1 from Influenza & Melan-A from Melanoma provides protein epitope for antigen recognition
The BactoVax vaccine platform has been engineered to act as a general vaccine platform, suitable for vaccination against bacteria, viruses, and tumors. Our current system has been engineered to express both viral antigen FluM1 and cancer surface antigen Melan-A to illustrate the modular nature of the platform itself. Instead of having to engineer a separate vaccine for every single different strain of a particular disease or group of disease separately, BactoVax provides a chassis that can be easily modified simply by addition of the nucleotide sequence for antigen of interest to trigger a specialized immune response.
